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Overview {#bph13880-sec-0003}
========

Nuclear receptors are specialised transcription factors with commonalities of sequence and structure, which bind as homo‐ or heterodimers to specific consensus sequences of DNA (response elements) in the promoter region of particular target genes. They regulate (either promoting or repressing) transcription of these target genes in response to a variety of endogenous ligands. Endogenous agonists are hydrophobic entities which, when bound to the receptor promote conformational changes in the receptor to allow recruitment (or dissociation) of protein partners, generating a large multiprotein complex.

Two major subclasses of nuclear receptors with identified endogenous agonists can be identified: steroid and non‐steroid hormone receptors. Steroid hormone receptors function typically as dimeric entities and are thought to be resident outside the nucleus in the unliganded state in a complex with chaperone proteins, which are liberated upon agonist binding. Migration to the nucleus and interaction with other regulators of gene transcription, including RNA polymerase, acetyltransferases and deacetylases, allows gene transcription to be regulated. Non‐steroid hormone receptors typically exhibit a greater distribution in the nucleus in the unliganded state and interact with other nuclear receptors to form heterodimers, as well as with other regulators of gene transcription, leading to changes in gene transcription upon agonist binding.

Selectivity of gene regulation is brought about through interaction of nuclear receptors with particular consensus sequences of DNA, which are arranged typically as repeats or inverted palindromes to allow accumulation of multiple transcription factors in the promoter regions of genes.

Family structure {#bph13880-sec-0004}
================

S209 1A. Thyroid hormone receptors S210 1B. Retinoic acid receptors S210 1C. Peroxisome proliferator‐activated receptors S211 1D. Rev‐Erb receptors S212 1F. Retinoic acid‐related orphans S212 1H. Liver X receptor‐like receptors S213 1I. Vitamin D receptor‐like receptors S214 2A. Hepatocyte nuclear factor‐4 receptors S215 2B. Retinoid X receptors S216 2C. Testicular receptors S216 2E. Tailless‐like receptors S217 2F. COUP‐TF‐like receptors S217 3B. Estrogen‐related receptors S218 4A. Nerve growth factor IB‐like receptors S219 5A. Fushi tarazu F1‐like receptors S219 6A. Germ cell nuclear factor receptors S220 0B. DAX‐like receptors S221 Steroid hormone receptors S221 3A. Estrogen receptors S221 3C. 3‐Ketosteroid receptors

[1A. Thyroid hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=698) {#bph13880-sec-0005}
==========================================================================================================

Overview {#bph13880-sec-0006}
--------

Thyroid hormone receptors (TRs, nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[41](http://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine ([T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)) and thyroid hormone ([triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. [NH‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2633) has been described as an antagonist at TRs with modest selectivity for TR*β*\[[110](http://www.ncbi.nlm.nih.gov/pubmed/12109914?dopt=AbstractPlus)\].

Nomenclature[Thyroid hormone receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=588)[Thyroid hormone receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589)Systematic nomenclatureNR1A1NR1A2HGNC, UniProt[THRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11796), [P10827](http://www.uniprot.org/uniprot/P10827)[THRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11799), [P10828](http://www.uniprot.org/uniprot/P10828)Rank order of potency[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)\>[T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)\>[T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)Agonists[dextrothyroxine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951) \[[19](http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus)\][dextrothyroxine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951) \[[19](http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus)\]Selective agonists--[sobetirome](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2639) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/9653548?dopt=AbstractPlus), [130](http://www.ncbi.nlm.nih.gov/pubmed/269396?dopt=AbstractPlus)\]

Comments {#bph13880-sec-0007}
--------

An interaction with integrin *α*V*β*3 has been suggested to underlie plasma membrane localization of TRs and non‐genomic signalling \[[8](http://www.ncbi.nlm.nih.gov/pubmed/15802494?dopt=AbstractPlus)\].One splice variant, TR*α* ~2~, lacks a functional DNA‐binding domain and appears to act as a transcription suppressor.

Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.

Further reading on 1A. Thyroid hormone receptors {#bph13880-sec-0008}
------------------------------------------------

Davis PJ et al. (2016) Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 12: 111‐21 [\[PMID:26668118\]](https://www.ncbi.nlm.nih.gov/pubmed/26668118?dopt=AbstractPlus)

Elbers LP et al. (2016) Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges. Curr Atheroscler Rep 18: 14 [\[PMID:26886134\]](http://www.ncbi.nlm.nih.gov/pubmed/26886134?dopt=AbstractPlus)

Flamant F et al. (2006) International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58: 705‐11 [\[PMID:17132849\]](http://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus)

Mendoza A et al. (2017) New insights into thyroid hormone action. Pharmacol Ther 173: 135‐145 [\[PMID:28174093\]](https://www.ncbi.nlm.nih.gov/pubmed/28174093?dopt=AbstractPlus)

[1B. Retinoic acid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=85) {#bph13880-sec-0009}
=======================================================================================================

Overview {#bph13880-sec-0010}
--------

Retinoic acid receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[46](http://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1B family activated by the vitamin A‐derived agonists [tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (ATRA) and [alitretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645), and the RAR‐selective synthetic agonists [TTNPB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2646) and [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429). [BMS493](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2641) is a family‐selective antagonist \[[47](http://www.ncbi.nlm.nih.gov/pubmed/19477412?dopt=AbstractPlus)\].

Nomenclature[Retinoic acid receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=590)[Retinoic acid receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=591)[Retinoic acid receptor‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=592)Systematic nomenclatureNR1B1NR1B2NR1B3HGNC, UniProt[RARA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9864), [P10276](http://www.uniprot.org/uniprot/P10276)[RARB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9865), [P10826](http://www.uniprot.org/uniprot/P10826)[RARG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9866), [P13631](http://www.uniprot.org/uniprot/P13631)Agonists[tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\]Sub/family‐selective agonists[tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\], [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\][tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\], [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\]Selective agonists[BMS753](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2650) \[[53](http://www.ncbi.nlm.nih.gov/pubmed/10421757?dopt=AbstractPlus)\], [tamibarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2648) \[[146](http://www.ncbi.nlm.nih.gov/pubmed/20925433?dopt=AbstractPlus)\], [Ro 40‐6055](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2647) \[[33](http://www.ncbi.nlm.nih.gov/pubmed/1656191?dopt=AbstractPlus)\][AC261066](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4054) \[[89](http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus)\], [AC55649](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4055) \[[88](http://www.ncbi.nlm.nih.gov/pubmed/19239230?dopt=AbstractPlus), [89](http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus)\][AHPN](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3431) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\]Selective antagonists[Ro 41‐5253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642) (pIC~50~ 6.3--7.2) \[[2](http://www.ncbi.nlm.nih.gov/pubmed/1323127?dopt=AbstractPlus), [69](http://www.ncbi.nlm.nih.gov/pubmed/8264595?dopt=AbstractPlus)\]--[MM 11253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4062) \[[76](http://www.ncbi.nlm.nih.gov/pubmed/10723137?dopt=AbstractPlus)\]

Comments {#bph13880-sec-0011}
--------

[Ro 41‐5253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642) has been suggested to be a PPAR*γ* agonist \[[129](http://www.ncbi.nlm.nih.gov/pubmed/17290005?dopt=AbstractPlus)\]. [LE135](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3433) is an antagonist with selectivity for RAR*α* and RAR*β* compared with RAR*γ*\[[84](http://www.ncbi.nlm.nih.gov/pubmed/10331664?dopt=AbstractPlus)\].

Further reading on 1B. Retinoic acid receptors {#bph13880-sec-0012}
----------------------------------------------

Duong V et al. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim. Biophys. Acta 1812: 1023‐31 [\[PMID:20970498\]](http://www.ncbi.nlm.nih.gov/pubmed/20970498?dopt=AbstractPlus)

Germain P et al. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev. 58: 712‐25 [\[PMID:17132850\]](http://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus)

Larange A et al. (2016) Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System. Annu Rev Immunol 34: 369‐94 [\[PMID:27168242\]](https://www.ncbi.nlm.nih.gov/pubmed/27168242?dopt=AbstractPlus)

Saeed A et al. (2017) The interrelationship between bile acid and vitamin A homeostasis. Biochim Biophys Acta 1862: 496‐512 [\[PMID:28111285\]](https://www.ncbi.nlm.nih.gov/pubmed/28111285?dopt=AbstractPlus)

[1C. Peroxisome proliferator‐activated receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86) {#bph13880-sec-0013}
===========================================================================================================================

Overview {#bph13880-sec-0014}
--------

Peroxisome proliferator‐activated receptors (PPARs, nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[101](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1C family, with diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. PPARs have many potential endogenous agonists \[[13](http://www.ncbi.nlm.nih.gov/pubmed/12749590?dopt=AbstractPlus), [101](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)\], including [15‐deoxy‐Δ^12,14^‐PGJ~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1877), prostacyclin ([PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)), many fatty acids and their oxidation products, lysophosphatidic acid ([LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906)) \[[98](http://www.ncbi.nlm.nih.gov/pubmed/12502787?dopt=AbstractPlus)\], [13‐HODE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5426), [15S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401), [Paz‐PC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5427), [azelaoyl‐PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5428) and leukotriene B4 ([LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487)). [Bezafibrate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2668) acts as a non‐selective agonist for the PPAR family \[[155](http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus)\]. These receptors also bind hypolipidaemic drugs (PPAR*α*) and anti‐diabetic thiazolidinediones (PPAR*γ*), as well as many non‐steroidal anti‐inflammatory drugs, such as [sulindac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5425) and [indomethacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909). Once activated by a ligand, the receptor forms a heterodimer with members of the retinoid X receptor family and can act as a transcription factor. Although radioligand binding assays have been described for all three receptors, the radioligands are not commercially available. Commonly, receptor occupancy studies are conducted using fluorescent ligands and truncated forms of the receptor limited to the ligand binding domain.

Nomenclature[Peroxisome proliferator‐activated receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593)[Peroxisome proliferator‐activated receptor‐*β*/*δ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=594)[Peroxisome proliferator‐activated receptor‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=595)Systematic nomenclatureNR1C1NR1C2NR1C3HGNC, UniProt[PPARA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9232), [Q07869](http://www.uniprot.org/uniprot/Q07869)[PPARD](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9235), [Q03181](http://www.uniprot.org/uniprot/Q03181)[PPARG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9236), [P37231](http://www.uniprot.org/uniprot/P37231)Selective agonists[GW7647](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2674) \[[17](http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus), [18](http://www.ncbi.nlm.nih.gov/pubmed/11354382?dopt=AbstractPlus)\], [CP‐775146](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6691) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/18971326?dopt=AbstractPlus)\], [pirinixic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2666) \[[155](http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus)\], [gemfibrozil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439) \[[31](http://www.ncbi.nlm.nih.gov/pubmed/21889235?dopt=AbstractPlus)\][GW0742X](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2686) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/15939051?dopt=AbstractPlus), [148](http://www.ncbi.nlm.nih.gov/pubmed/12699745?dopt=AbstractPlus)\], [GW501516](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2687) \[[112](http://www.ncbi.nlm.nih.gov/pubmed/11309497?dopt=AbstractPlus)\][GW1929](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2703) \[[17](http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus)\], [bardoxolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2717) (Partial agonist) \[[149](http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus)\], [rosiglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [80](http://www.ncbi.nlm.nih.gov/pubmed/9013583?dopt=AbstractPlus), [86](http://www.ncbi.nlm.nih.gov/pubmed/11720854?dopt=AbstractPlus), [161](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [troglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2693) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [161](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [pioglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2694) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/8828476?dopt=AbstractPlus), [59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [127](http://www.ncbi.nlm.nih.gov/pubmed/11095972?dopt=AbstractPlus), [161](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [ciglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2711) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus)\]Selective antagonists[GW6471](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3440) (pIC~50~ 6.6) \[[158](http://www.ncbi.nlm.nih.gov/pubmed/11845213?dopt=AbstractPlus)\][GSK0660](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3441) (pIC~50~ 6.5) \[[131](http://www.ncbi.nlm.nih.gov/pubmed/17975020?dopt=AbstractPlus)\][T0070907](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3444) (p*K* ~i~ 9) \[[77](http://www.ncbi.nlm.nih.gov/pubmed/11877444?dopt=AbstractPlus)\], [GW9662](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3442) (Irreversible inhibition) (pIC~50~ 8.1) \[[78](http://www.ncbi.nlm.nih.gov/pubmed/12022867?dopt=AbstractPlus)\], [CDDO‐Me](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3443) (p*K* ~i~ 6.9) \[[149](http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus)\]

Comments {#bph13880-sec-0015}
--------

As with the estrogen receptor antagonists, many agents show tissue‐selective efficacy (e.g. \[[12](http://www.ncbi.nlm.nih.gov/pubmed/11030710?dopt=AbstractPlus), [109](http://www.ncbi.nlm.nih.gov/pubmed/11991651?dopt=AbstractPlus), [124](http://www.ncbi.nlm.nih.gov/pubmed/11684010?dopt=AbstractPlus)\]). Agonists with mixed activity at PPAR*α* and PPAR*γ* have also been described (e.g \[[35](http://www.ncbi.nlm.nih.gov/pubmed/15120604?dopt=AbstractPlus), [52](http://www.ncbi.nlm.nih.gov/pubmed/14701675?dopt=AbstractPlus), [159](http://www.ncbi.nlm.nih.gov/pubmed/15115385?dopt=AbstractPlus)\]).

Further reading on 1C. Peroxisome proliferator‐activated receptors {#bph13880-sec-0016}
------------------------------------------------------------------

Cheang WS et al. (2015) The peroxisome proliferator‐activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol 172: 5512‐22 [\[PMID:25438608\]](https://www.ncbi.nlm.nih.gov/pubmed/25438608?dopt=AbstractPlus)

Gross B et al. (2017) PPARs in obesity‐induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13: 36‐49 [\[PMID:27636730\]](https://www.ncbi.nlm.nih.gov/pubmed/27636730?dopt=AbstractPlus)

Hallenborg P et al. (2016) The elusive endogenous adipogenic PPARgamma agonists: Lining up the suspects. Prog Lipid Res 61: 149‐62 [\[PMID:26703188\]](https://www.ncbi.nlm.nih.gov/pubmed/26703188?dopt=AbstractPlus)

Michalik L et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator‐activated receptors. Pharmacol. Rev. 58: 726‐41 [\[PMID:17132851\]](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)

Sauer S. (2015) Ligands for the Nuclear Peroxisome Proliferator‐Activated Receptor Gamma. Trends Pharmacol Sci 36: 688‐704 [\[PMID:26435213\]](https://www.ncbi.nlm.nih.gov/pubmed/26435213?dopt=AbstractPlus)

[1D. Rev‐Erb receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=87) {#bph13880-sec-0017}
=================================================================================================

Overview {#bph13880-sec-0018}
--------

Rev‐erb receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand, but are thought to be activated by heme.

Nomenclature[Rev‐Erb‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=596)[Rev‐Erb‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=597)Systematic nomenclatureNR1D1NR1D2HGNC, UniProt[NR1D1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7962), [P20393](http://www.uniprot.org/uniprot/P20393)[NR1D2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7963), [Q14995](http://www.uniprot.org/uniprot/Q14995)Endogenous agonists[heme](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349) \[[121](http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus), [160](http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus)\][heme](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349) \[[97](http://www.ncbi.nlm.nih.gov/pubmed/24872411?dopt=AbstractPlus), [121](http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus), [160](http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus)\]Selective agonists[GSK4112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903) \[[51](http://www.ncbi.nlm.nih.gov/pubmed/20677822?dopt=AbstractPlus)\], [GSK4112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903) \[[70](http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus)\]--Selective antagonists[SR8278](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2904) (pIC~50~ 6.5) \[[70](http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus)\]--

Further reading on 1D. Rev‐Erb receptors {#bph13880-sec-0019}
----------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Gonzalez‐Sanchez E et al. (2015) Nuclear receptors in acute and chronic cholestasis. Dig Dis 33: 357‐66 [\[PMID:26045270\]](http://www.ncbi.nlm.nih.gov/pubmed/26045270?dopt=AbstractPlus)

Gustafson CL et al. (2015) Emerging models for the molecular basis of mammalian circadian timing. Biochemistry 54: 134‐49 [\[PMID:25303119\]](https://www.ncbi.nlm.nih.gov/pubmed/25303119?dopt=AbstractPlus)

Sousa EH et al. (2017) Drug discovery targeting heme‐based sensors and their coupled activities. J Inorg Biochem 167: 12‐20 [\[PMID:27893989\]](https://www.ncbi.nlm.nih.gov/pubmed/27893989?dopt=AbstractPlus)

[1F. Retinoic acid‐related orphans](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=88) {#bph13880-sec-0020}
=============================================================================================================

Overview {#bph13880-sec-0021}
--------

Retinoic acid receptor‐related orphan receptors (ROR, nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be assigned a definitive endogenous ligand, although ROR*α* may be synthesized with a 'captured' agonist such as [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718)\[[65](http://www.ncbi.nlm.nih.gov/pubmed/14722075?dopt=AbstractPlus), [66](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus)\].

Nomenclature[RAR‐related orphan receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=598)[RAR‐related orphan receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=599)[RAR‐related orphan receptor‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=600)Systematic nomenclatureNR1F1NR1F2NR1F3HGNC, UniProt[RORA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10258), [P35398](http://www.uniprot.org/uniprot/P35398)[RORB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10259), [Q92753](http://www.uniprot.org/uniprot/Q92753)[RORC](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10260), [P51449](http://www.uniprot.org/uniprot/P51449)Endogenous agonists[cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) \[[66](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus), [114](http://www.ncbi.nlm.nih.gov/pubmed/8858107?dopt=AbstractPlus)\]----Selective agonists[7‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3432) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus)\], [cholesterol sulphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2738) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus), [66](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus)\]----

Comments {#bph13880-sec-0022}
--------

[tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) shows selectivity for ROR*β* within the ROR family \[[136](http://www.ncbi.nlm.nih.gov/pubmed/12958591?dopt=AbstractPlus)\]. ROR*α* has been suggested to be a nuclear receptor responding to [melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224)\[[154](http://www.ncbi.nlm.nih.gov/pubmed/7885826?dopt=AbstractPlus)\].

Further reading on 1F. Retinoic acid‐related orphans {#bph13880-sec-0023}
----------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Cyr P et al. (2016) Recent progress on nuclear receptor RORgamma modulators. Bioorg Med Chem Lett 26: 4387‐93 [\[PMID:27542308\]](https://www.ncbi.nlm.nih.gov/pubmed/27542308?dopt=AbstractPlus)

Dahlman‐Wright K et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58: 685‐704 [\[PMID:17132848\]](https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Guillemot‐Legris O et al. (2016) Oxysterols in Metabolic Syndrome: From Bystander Molecules to Bioactive Lipids. Trends Mol Med 22: 594‐614 [\[PMID:27286741\]](https://www.ncbi.nlm.nih.gov/pubmed/27286741?dopt=AbstractPlus)

Mutemberezi V et al. (2016) Oxysterols: From cholesterol metabolites to key mediators. Prog Lipid Res 64: 152‐169 [\[PMID:27687912\]](https://www.ncbi.nlm.nih.gov/pubmed/27687912?dopt=AbstractPlus)

[1H. Liver X receptor‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=89) {#bph13880-sec-0024}
===============================================================================================================

Overview {#bph13880-sec-0025}
--------

Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[105](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\]) are members of a steroid analogue‐activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs appear to be activated by bile acids.

Nomenclature[Farnesoid X receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=603)[Farnesoid X receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=604)[Liver X receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602)[Liver X receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=601)Systematic nomenclatureNR1H4NR1H5NR1H3NR1H2HGNC, UniProt[NR1H4](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7967), [Q96RI1](http://www.uniprot.org/uniprot/Q96RI1)[NR1H5P](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32673), --[NR1H3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7966), [Q13133](http://www.uniprot.org/uniprot/Q13133)[NR1H2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7965), [P55055](http://www.uniprot.org/uniprot/P55055)Potency order[chenodeoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=608)\>[lithocholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611), [deoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610) \[[92](http://www.ncbi.nlm.nih.gov/pubmed/10334992?dopt=AbstractPlus), [115](http://www.ncbi.nlm.nih.gov/pubmed/10334993?dopt=AbstractPlus)\]--[20S‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434), [22R‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742), [24(S)‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750)\>[25‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885), [27‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752) \[[79](http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus)\][20S‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434), [22R‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742), [24(S)‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750)\>[25‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885), [27‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752) \[[79](http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus)\]Endogenous agonists--[lanosterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746) \[[113](http://www.ncbi.nlm.nih.gov/pubmed/12529392?dopt=AbstractPlus)\] -- Mouse----Selective agonists[GW4064](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2743) \[[94](http://www.ncbi.nlm.nih.gov/pubmed/10956205?dopt=AbstractPlus)\], [obeticholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3435) \[[116](http://www.ncbi.nlm.nih.gov/pubmed/12166927?dopt=AbstractPlus)\], [fexaramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2744) \[[36](http://www.ncbi.nlm.nih.gov/pubmed/12718892?dopt=AbstractPlus)\]------Selective antagonists[guggulsterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2745) (pIC~50~ 5.7--6) \[[157](http://www.ncbi.nlm.nih.gov/pubmed/12089353?dopt=AbstractPlus)\]------

Comments {#bph13880-sec-0026}
--------

[T0901317](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755)\[[122](http://www.ncbi.nlm.nih.gov/pubmed/10968783?dopt=AbstractPlus)\] and [GW3965](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2754)\[[27](http://www.ncbi.nlm.nih.gov/pubmed/11985463?dopt=AbstractPlus)\] are synthetic agonists acting at both LXR*α* and LXR*β* with less than 10‐fold selectivity.

Further reading on 1H. Liver X receptor‐like receptors {#bph13880-sec-0027}
------------------------------------------------------

Courtney R et al. (2016) LXR Regulation of Brain Cholesterol: From Development to Disease. Trends Endocrinol Metab 27: 404‐14 [\[PMID:27113081\]](https://www.ncbi.nlm.nih.gov/pubmed/27113081?dopt=AbstractPlus)

Gadaleta RM et al. (2017) Bile acids and colon cancer: Is FXR the solution of the conundrum? Mol Aspects Med [\[PMID:28400119\]](https://www.ncbi.nlm.nih.gov/pubmed/28400119?dopt=AbstractPlus)

Merlen G et al. (2017) Bile acids and their receptors during liver regeneration: \"Dangerous protectors\". Mol Aspects Med [\[PMID:28302491\]](https://www.ncbi.nlm.nih.gov/pubmed/28302491?dopt=AbstractPlus)

Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 58: 742‐59 [\[PMID:17132852\]](https://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)

Mouzat K et al. (2016) Liver X receptors: from cholesterol regulation to neuroprotection‐a new barrier against neurodegeneration in amyotrophic lateral sclerosis? Cell Mol Life Sci 73: 3801‐8

Schulman IG. (2017) Liver X receptors link lipid metabolism and inflammation. FEBS Lett [\[PMID:28555747\]](https://www.ncbi.nlm.nih.gov/pubmed/28555747?dopt=AbstractPlus)

[1I. Vitamin D receptor‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=90) {#bph13880-sec-0028}
=================================================================================================================

Overview {#bph13880-sec-0029}
--------

Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[105](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds, with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR \[[105](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\].

Nomenclature[Vitamin D receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=605)[Pregnane X receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=606)[Constitutive androstane receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=607)Systematic nomenclatureNR1I1NR1I2NR1I3HGNC, UniProt[VDR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12679), [P11473](http://www.uniprot.org/uniprot/P11473)[NR1I2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7968), [O75469](http://www.uniprot.org/uniprot/O75469)[NR1I3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7969), [Q14994](http://www.uniprot.org/uniprot/Q14994)Endogenous agonists[1,25‐dihydroxyvitamin D3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779) \[[11](http://www.ncbi.nlm.nih.gov/pubmed/7976510?dopt=AbstractPlus), [39](http://www.ncbi.nlm.nih.gov/pubmed/12089348?dopt=AbstractPlus)\][17*β*‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus)\]--Selective agonists[seocalcitol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2777) \[[28](http://www.ncbi.nlm.nih.gov/pubmed/1472092?dopt=AbstractPlus), [153](http://www.ncbi.nlm.nih.gov/pubmed/8573413?dopt=AbstractPlus)\], [doxercalciferol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2790)[hyperforin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2764) \[[106](http://www.ncbi.nlm.nih.gov/pubmed/10852961?dopt=AbstractPlus), [152](http://www.ncbi.nlm.nih.gov/pubmed/10974665?dopt=AbstractPlus)\], [5*β*‐pregnane‐3,20‐dione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2759) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus)\], [lovastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739) \[[81](http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus)\], [rifampicin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765) \[[15](http://www.ncbi.nlm.nih.gov/pubmed/9784494?dopt=AbstractPlus), [81](http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus)\][TCPOBOP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2756) \[[144](http://www.ncbi.nlm.nih.gov/pubmed/10757780?dopt=AbstractPlus)\] -- Mouse, [CITCO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2758) \[[91](http://www.ncbi.nlm.nih.gov/pubmed/12611900?dopt=AbstractPlus)\]Selective antagonists[TEI‐9647](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2788) (pIC~50~ 8.2) \[[126](http://www.ncbi.nlm.nih.gov/pubmed/17125259?dopt=AbstractPlus)\] -- Chicken, [ZK159222](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2789) (pIC~50~ 7.5) \[[42](http://www.ncbi.nlm.nih.gov/pubmed/12901907?dopt=AbstractPlus), [60](http://www.ncbi.nlm.nih.gov/pubmed/11094341?dopt=AbstractPlus)\]----Comments----[clotrimazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330) \[[107](http://www.ncbi.nlm.nih.gov/pubmed/10748001?dopt=AbstractPlus)\] and [T0901317](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755) \[[68](http://www.ncbi.nlm.nih.gov/pubmed/23665929?dopt=AbstractPlus)\] although acting at other sites, function as antagonists of the constitutive androstane receptor.

Further reading on 1I. Vitamin D receptor‐like receptors {#bph13880-sec-0030}
--------------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Long MD et al. (2015) Vitamin D receptor and RXR in the post‐genomic era. J Cell Physiol. 230: 758‐66 [\[PMID:25335912\]](http://www.ncbi.nlm.nih.gov/pubmed/253359122?dopt=AbstractPlus)

Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol. Rev. 58: 742‐59 [\[PMID:17132852\]](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)

[2A. Hepatocyte nuclear factor‐4 receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=91) {#bph13880-sec-0031}
=====================================================================================================================

Overview {#bph13880-sec-0032}
--------

The nomenclature of hepatocyte nuclear factor‐4 receptors is agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]. While linoleic acid has been identified as the endogenous ligand for HNF4*α* its function remains ambiguous \[[163](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\]. HNF4*γ* has yet to be paired with an endogenous ligand.

Nomenclature[Hepatocyte nuclear factor‐4‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=608)[Hepatocyte nuclear factor‐4‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=609)Systematic nomenclatureNR2A1NR2A2HGNC, UniProt[HNF4A](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5024), [P41235](http://www.uniprot.org/uniprot/P41235)[HNF4G](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5026), [Q14541](http://www.uniprot.org/uniprot/Q14541)Endogenous agonists[linoleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052) \[[163](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\]--Selective antagonists[BI6015](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6695) \[[71](http://www.ncbi.nlm.nih.gov/pubmed/22840769?dopt=AbstractPlus)\]--CommentsHNF4*α* has constitutive transactivation activity \[[163](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\] and binds DNA as a homodimer \[[63](http://www.ncbi.nlm.nih.gov/pubmed/7651430?dopt=AbstractPlus)\].--

Further reading on 2A. Hepatocyte nuclear factor‐4 receptors {#bph13880-sec-0033}
------------------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Garattini E et al. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. Oncotarget 7: 42661‐42682 [\[PMID:26894976\]](https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus)

Lu H. (2016) Crosstalk of HNF4alpha with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B 6: 393‐408 [\[PMID:27709008\]](https://www.ncbi.nlm.nih.gov/pubmed/27709008?dopt=AbstractPlus)

Walesky CE et al. (2015) Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation and cancer. Gene Expr 16: 101‐8[\[PMID:25700366\]](https://www.ncbi.nlm.nih.gov/pubmed/25700366?dopt=AbstractPlus)

[2B. Retinoid X receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=92) {#bph13880-sec-0034}
====================================================================================================

Overview {#bph13880-sec-0035}
--------

Retinoid X receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[45](http://www.ncbi.nlm.nih.gov/pubmed/17132853?dopt=AbstractPlus)\]) are NR2B family members activated by [alitretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645) and the RXR‐selective agonists [bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) and [LG100268](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2808), sometimes referred to as rexinoids. [UVI3003](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2816)\[[108](http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=AbstractPlus)\] and [HX 531](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8079) \[[37](http://www.ncbi.nlm.nih.gov/pubmed/10748721?dopt=AbstractPlus)\] have been described as a pan‐RXR antagonists. These receptors form RXR‐RAR heterodimers and RXR‐RXR homodimers \[[22](http://www.ncbi.nlm.nih.gov/pubmed/8801176?dopt=AbstractPlus), [96](http://www.ncbi.nlm.nih.gov/pubmed/8521508?dopt=AbstractPlus)\].

Nomenclature[Retinoid X receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=610)[Retinoid X receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=611)[Retinoid X receptor‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=612)Systematic nomenclatureNR2B1NR2B2NR2B3HGNC, UniProt[RXRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10477), [P19793](http://www.uniprot.org/uniprot/P19793)[RXRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10478), [P28702](http://www.uniprot.org/uniprot/P28702)[RXRG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10479), [P48443](http://www.uniprot.org/uniprot/P48443)Sub/family‐selective agonists[bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [21](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [141](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\][bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [21](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [141](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\][bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [21](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [141](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\]Selective agonists[CD3254](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2810) \[[48](http://www.ncbi.nlm.nih.gov/pubmed/11805839?dopt=AbstractPlus)\]----

Further reading on 2B. Retinoid X receptors {#bph13880-sec-0036}
-------------------------------------------

Germain P et al. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 58: 760‐72 [\[PMID:17132853\]](http://www.ncbi.nlm.nih.gov/pubmed/17132853?dopt=AbstractPlus)

Long MD et al. (2015) Vitamin D receptor and RXR in the post‐genomic era. J Cell Physiol 230: 758‐66 [\[PMID:25335912\]](https://www.ncbi.nlm.nih.gov/pubmed/25335912?dopt=AbstractPlus)

Menendez‐Gutierrez MP et al. (2017) The multi‐faceted role of retinoid X receptor in bone remodeling. Cell Mol Life Sci 74: 2135‐2149 [\[PMID:28105491\]](https://www.ncbi.nlm.nih.gov/pubmed/28105491?dopt=AbstractPlus)

[2C. Testicular receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=93) {#bph13880-sec-0037}
====================================================================================================

Overview {#bph13880-sec-0038}
--------

Testicular receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand, although testicular receptor 4 has been reported to respond to retinoids.

Nomenclature[Testicular receptor 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=613)[Testicular receptor 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=614)Systematic nomenclatureNR2C1NR2C2HGNC, UniProt[NR2C1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7971), [P13056](http://www.uniprot.org/uniprot/P13056)[NR2C2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7972), [P49116](http://www.uniprot.org/uniprot/P49116)Endogenous agonists--[retinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053) \[[169](http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus)\], [tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) \[[169](http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus)\]CommentsForms a heterodimer with TR4; gene disruption appears without effect on testicular development or function \[[132](http://www.ncbi.nlm.nih.gov/pubmed/12052874?dopt=AbstractPlus)\].Forms a heterodimer with TR2.

Further reading on 2C. Testicular receptors {#bph13880-sec-0039}
-------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Dahlman‐Wright K et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58: 685‐704 [\[PMID:17132848\]](https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol 28: 157‐72 [\[PMID:24295738\]](https://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus)

Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim. Biophys. Acta 1866: 23‐36 [\[PMID:27264242\]](http://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus)

[2E. Tailless‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=94) {#bph13880-sec-0040}
=======================================================================================================

Overview {#bph13880-sec-0041}
--------

Tailless‐like receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[TLX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=615)[PNR](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=616)Systematic nomenclatureNR2E1NR2E3HGNC, UniProt[NR2E1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7973), [Q9Y466](http://www.uniprot.org/uniprot/Q9Y466)[NR2E3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7974), [Q9Y5X4](http://www.uniprot.org/uniprot/Q9Y5X4)CommentsGene disruption is associated with abnormal brain development \[[75](http://www.ncbi.nlm.nih.gov/pubmed/12902391?dopt=AbstractPlus), [104](http://www.ncbi.nlm.nih.gov/pubmed/9394001?dopt=AbstractPlus)\].--

Further reading on 2E. Tailless‐like receptors {#bph13880-sec-0042}
----------------------------------------------

Benod C et al. (2016) TLX: An elusive receptor. J. Steroid Biochem. Mol. Biol. 157: 41‐7 [\[PMID:26554934\]](http://www.ncbi.nlm.nih.gov/pubmed/26554934?dopt=AbstractPlus)

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

[2F. COUP‐TF‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=95) {#bph13880-sec-0043}
======================================================================================================

Overview {#bph13880-sec-0044}
--------

COUP‐TF‐like receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[COUP‐TF1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=617)[COUP‐TF2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=618)[V‐erbA‐related gene](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=619)Systematic nomenclatureNR2F1NR2F2NR2F6HGNC, UniProt[NR2F1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7975), [P10589](http://www.uniprot.org/uniprot/P10589)[NR2F2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7976), [P24468](http://www.uniprot.org/uniprot/P24468)[NR2F6](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7977), [P10588](http://www.uniprot.org/uniprot/P10588)CommentsGene disruption is perinatally lethal \[[120](http://www.ncbi.nlm.nih.gov/pubmed/9271116?dopt=AbstractPlus)\].Gene disruption is embryonically lethal \[[117](http://www.ncbi.nlm.nih.gov/pubmed/10215630?dopt=AbstractPlus)\].Gene disruption impairs CNS development \[[151](http://www.ncbi.nlm.nih.gov/pubmed/15741322?dopt=AbstractPlus)\].

Further reading on 2F. COUP‐TF‐like receptors {#bph13880-sec-0045}
---------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim. Biophys. Acta 1866: 23‐36 [\[PMID:27264242\]](http://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus)

Wu SP et al. (2016) Choose your destiny: Make a cell fate decision with COUP‐TFII. J Steroid Biochem Mol Biol 157: 7‐12 [\[PMID:26658017\]](https://www.ncbi.nlm.nih.gov/pubmed/26658017?dopt=AbstractPlus)

[3B. Estrogen‐related receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=97) {#bph13880-sec-0046}
==========================================================================================================

Overview {#bph13880-sec-0047}
--------

Estrogen‐related receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[Estrogen‐related receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622)[Estrogen‐related receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=623)[Estrogen‐related receptor‐*γ*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=624)Systematic nomenclatureNR3B1NR3B2NR3B3HGNC, UniProt[ESRRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3471), [P11474](http://www.uniprot.org/uniprot/P11474)[ESRRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3473), [O95718](http://www.uniprot.org/uniprot/O95718)[ESRRG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3474), [P62508](http://www.uniprot.org/uniprot/P62508)CommentsActivated by some dietary flavonoids \[[138](http://www.ncbi.nlm.nih.gov/pubmed/14638870?dopt=AbstractPlus)\]; activated by the synthetic agonist [GSK4716](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2835) \[[181](http://www.ncbi.nlm.nih.gov/pubmed/15857113?dopt=AbstractPlus)\] and blocked by [XCT790](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2832) \[[156](http://www.ncbi.nlm.nih.gov/pubmed/15184675?dopt=AbstractPlus)\].May be activated by [DY131](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834) \[[162](http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus)\].May be activated by [DY131](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834) \[[162](http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus)\].

Further reading on 3B. Estrogen‐related receptors {#bph13880-sec-0048}
-------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Divekar SD et al. (2016) Estrogen‐related receptor *β*(ERR*β*) ‐ renaissance receptor or receptor renaissance? Nucl Recept Signal 14: e002 [\[PMID:27507929\]](http://www.ncbi.nlm.nih.gov/pubmed/27507929?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Tam IS et al. (2016) There and back again: The journey of the estrogen‐related receptors in the cancer realm. J Steroid Biochem Mol Biol 157: 13‐9[\[PMID:26151739\]](https://www.ncbi.nlm.nih.gov/pubmed/26151739?dopt=AbstractPlus)

Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim. Biophys. Acta 1866: 23‐36 [\[PMID:27264242\]](http://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus)

[4A. Nerve growth factor IB‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=99) {#bph13880-sec-0049}
=====================================================================================================================

Overview {#bph13880-sec-0050}
--------

Nerve growth factor IB‐like receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[Nerve Growth factor IB](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=629)[Nuclear receptor related 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=630)[Neuron‐derived orphan receptor 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=631)Systematic nomenclatureNR4A1NR4A2NR4A3HGNC, UniProt[NR4A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7980), [P22736](http://www.uniprot.org/uniprot/P22736)[NR4A2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7981), [P43354](http://www.uniprot.org/uniprot/P43354)[NR4A3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7982), [Q92570](http://www.uniprot.org/uniprot/Q92570)CommentsAn endogenous agonist, [cytosporone B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5424), has been described \[[164](http://www.ncbi.nlm.nih.gov/pubmed/18690216?dopt=AbstractPlus)\], although structural analysis and molecular modelling has not identified a ligand binding site \[[4](http://www.ncbi.nlm.nih.gov/pubmed/12809604?dopt=AbstractPlus), [40](http://www.ncbi.nlm.nih.gov/pubmed/15716272?dopt=AbstractPlus), [150](http://www.ncbi.nlm.nih.gov/pubmed/12774125?dopt=AbstractPlus)\].----

Further reading on 4A. Nerve growth factor IB‐like receptors {#bph13880-sec-0051}
------------------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Ranhotra HS. (2015) The NR4A orphan nuclear receptors: mediators in metabolism and diseases. J Recept Signal Transduct Res 35: 184‐8 [\[PMID:25089663\]](https://www.ncbi.nlm.nih.gov/pubmed/25089663?dopt=AbstractPlus)

Rodriguez‐Calvo R et al. (2017) The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 21: 291‐304 [\[PMID:28055275\]](https://www.ncbi.nlm.nih.gov/pubmed/28055275?dopt=AbstractPlus)

Safe S et al. (2016) Nuclear receptor 4A (NR4A) family ‐ orphans no more. J Steroid Biochem Mol Biol 157: 48‐60 [\[PMID:25917081\]](https://www.ncbi.nlm.nih.gov/pubmed/25917081?dopt=AbstractPlus)

[5A. Fushi tarazu F1‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=100) {#bph13880-sec-0052}
===============================================================================================================

Overview {#bph13880-sec-0053}
--------

Fushi tarazu F1‐like receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[Steroidogenic factor 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=632)[Liver receptor homolog‐1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=633)Systematic nomenclatureNR5A1NR5A2HGNC, UniProt[NR5A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7983), [Q13285](http://www.uniprot.org/uniprot/Q13285)[NR5A2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7984), [O00482](http://www.uniprot.org/uniprot/O00482)CommentsReported to be inhibited by [AC45594](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5422) \[[32](http://www.ncbi.nlm.nih.gov/pubmed/18055761?dopt=AbstractPlus)\] and [SID7969543](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5423) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/18334597?dopt=AbstractPlus)\].--

Further reading on 5A. Fushi tarazu F1‐like receptors {#bph13880-sec-0054}
-----------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Garattini E et al. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. Oncotarget. 7: 42661‐42682 [\[PMID:26894976\]](http://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Zhi X et al. (2016) Structures and regulation of non‐X orphan nuclear receptors: A retinoid hypothesis. J Steroid Biochem Mol Biol. 157: 27‐40 [\[PMID:26159912\]](http://www.ncbi.nlm.nih.gov/pubmed/26159912?dopt=AbstractPlus)

Zimmer V et al. (2015) Nuclear receptor variants in liver disease. Dig Dis. 33: 415‐9 [\[PMID:26045277\]](http://www.ncbi.nlm.nih.gov/pubmed/26045277?dopt=AbstractPlus)

[6A. Germ cell nuclear factor receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=101) {#bph13880-sec-0055}
===================================================================================================================

Overview {#bph13880-sec-0056}
--------

Germ cell nuclear factor receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[Germ cell nuclear factor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=634)Systematic nomenclatureNR6A1HGNC, UniProt[NR6A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7985), [Q15406](http://www.uniprot.org/uniprot/Q15406)

Further reading on 6A. Germ cell nuclear factor receptors {#bph13880-sec-0057}
---------------------------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Garattini E et al. (2006) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. Oncotarget. 7: 42661‐42682 [\[PMID:26894976\]](http://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Safe S et al. ((2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol. 28: 157‐72 [\[PMID:24295738\]](http://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus)

Zhi X et al. (2016) Structures and regulation of non‐X orphan nuclear receptors: A retinoid hypothesis. J Steroid Biochem Mol Biol. 157: 27‐40 [\[PMID:26159912\]](http://www.ncbi.nlm.nih.gov/pubmed/26159912?dopt=AbstractPlus)

[0B. DAX‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=102) {#bph13880-sec-0058}
===================================================================================================

Overview {#bph13880-sec-0059}
--------

Dax‐like receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[6](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand.

Nomenclature[DAX1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=635)[SHP](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=636)Systematic nomenclatureNR0B1NR0B2HGNC, UniProt[NR0B1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7960), [P51843](http://www.uniprot.org/uniprot/P51843)[NR0B2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7961), [Q15466](http://www.uniprot.org/uniprot/Q15466)

Further reading on 0B. DAX‐like receptors {#bph13880-sec-0060}
-----------------------------------------

Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

Garattini E et al. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. Oncotarget 7: 42661‐42682 [\[PMID:26894976\]](https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus)

Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685‐704 [\[PMID:17132848\]](http://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus)

Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol 28: 157‐72 [\[PMID:24295738\]](https://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus)

Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim. Biophys. Acta 1866: 23‐36 [\[PMID:27264242\]](http://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus)

[Steroid hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=107) {#bph13880-sec-0061}
======================================================================================================

Overview {#bph13880-sec-0062}
--------

Steroid hormone receptors (nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[[30](http://www.ncbi.nlm.nih.gov/pubmed/17132854?dopt=AbstractPlus), [87](http://www.ncbi.nlm.nih.gov/pubmed/17132855?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR3 class, with endogenous agonists that may be divided into 3‐hydroxysteroids ([estrone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818) and [17*β*‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013)) and 3‐ketosteroids ([dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856)\[DHT\], [aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872), [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869), [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) and [testosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858)). These receptors exist as dimers coupled with chaperone molecules (such as [hsp90*β*](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5365)([HSP90AB1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5258), [P08238](http://www.uniprot.org/uniprot/P08238)) and immunophilin FKBP52:[FKBP4](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3720), [Q02790](http://www.uniprot.org/uniprot/Q02790)), which are shed on binding the steroid hormone. Although rapid signalling phenomena are observed \[[83](http://www.ncbi.nlm.nih.gov/pubmed/18784332?dopt=AbstractPlus), [119](http://www.ncbi.nlm.nih.gov/pubmed/19389460?dopt=AbstractPlus)\], the principal signalling cascade appears to involve binding of the activated receptors to nuclear hormone response elements of the genome, with a 15‐nucleotide consensus sequence AGAACAnnnTGTTCT (i.e. an inverted palindrome) as homo‐ or heterodimers. They also affect transcription by protein‐protein interactions with other transcription factors, such as activator protein 1 (AP‐1) and nuclear factor *κ*B (NF‐*κ*B). Splice variants of each of these receptors can form functional or non‐functional monomers that can dimerize to form functional or non‐functional receptors. For example, alternative splicing of PR mRNA produces A and B monomers that combine to produce functional AA, AB and BB receptors with distinct characteristics \[[145](http://www.ncbi.nlm.nih.gov/pubmed/8264658?dopt=AbstractPlus)\].

A 7TM receptor responsive to estrogen ([GPER1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4485), [Q99527](http://www.uniprot.org/uniprot/Q99527), also known as GPR30, see \[[118](http://www.ncbi.nlm.nih.gov/pubmed/18271749?dopt=AbstractPlus)\]) has been described. Human orthologues of 7TM \'membrane progestin receptors\' ([PAQR7](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23146), [PAQR8](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15708) and [PAQR5](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29645)), initially discovered in fish \[[170](http://www.ncbi.nlm.nih.gov/pubmed/12601167?dopt=AbstractPlus), [171](http://www.ncbi.nlm.nih.gov/pubmed/12574519?dopt=AbstractPlus)\], appear to localize to intracellular membranes and respond to \'non‐genomic\' progesterone analogues independently of G proteins \[[134](http://www.ncbi.nlm.nih.gov/pubmed/18603275?dopt=AbstractPlus)\].

[3A. Estrogen receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=96) {#bph13880-sec-0063}
==================================================================================================

Overview {#bph13880-sec-0064}
--------

Estrogen receptor (ER) activity regulates diverse physiological processes via transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The cellular environment defines the specific complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these determinants control the resulting biological response.

Nomenclature[Estrogen receptor‐*α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620)[Estrogen receptor‐*β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621)Systematic nomenclatureNR3A1NR3A2HGNC, UniProt[ESR1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3467), [P03372](http://www.uniprot.org/uniprot/P03372)[ESR2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3468), [Q92731](http://www.uniprot.org/uniprot/Q92731)Endogenous agonists[estriol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2821) \[[74](http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus)\], [estrone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818) \[[74](http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus)\]--Selective agonists[propylpyrazoletriol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2819) \[[73](http://www.ncbi.nlm.nih.gov/pubmed/11014206?dopt=AbstractPlus), [135](http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus)\], [ethinylestradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7071) \[[62](http://www.ncbi.nlm.nih.gov/pubmed/16722623?dopt=AbstractPlus)\][WAY200070](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4052) \[[93](http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus)\], [diarylpropionitrile](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2825) \[[100](http://www.ncbi.nlm.nih.gov/pubmed/11708925?dopt=AbstractPlus), [135](http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus)\], [prinaberel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6700) \[[29](http://www.ncbi.nlm.nih.gov/pubmed/18097065?dopt=AbstractPlus), [93](http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus)\]Sub/family‐selective antagonists[bazedoxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355) (pIC~50~ 7.6) \[[103](http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus)\][bazedoxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355) (pIC~50~ 7.1) \[[103](http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus)\]Selective antagonists[clomiphene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4159) (p*K* ~i~ 8.9) \[[3](#bph13880-bib-0003){ref-type="ref"}\], [methyl‐piperidino‐pyrazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3459) (p*K* ~i~ 8.6) \[[139](http://www.ncbi.nlm.nih.gov/pubmed/11861516?dopt=AbstractPlus)\][R,R‐THC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822) (p*K* ~i~ 8.4) \[[99](http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus), [140](http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus)\], [PHTPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3461) (p*K* ~i~ 6.9) \[[168](http://www.ncbi.nlm.nih.gov/pubmed/17228884?dopt=AbstractPlus)\]

Comments {#bph13880-sec-0065}
--------

[R,R‐THC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822) exhibits partial agonist activity at ER*α*\[[99](http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus), [140](http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus)\]. Estrogen receptors may be blocked non‐selectively by [tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016) and [raloxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820) and labelled by [\[^3^H\]17*β*‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1012) and [\[^3^H\]tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5384). Many agents thought initially to be antagonists at estrogen receptors appear to have tissue‐specific efficacy (e.g. [Tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016) is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). [Y134](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5430) has been suggested to be an ER*α*‐selective estrogen receptor modulator \[[111](http://www.ncbi.nlm.nih.gov/pubmed/17115070?dopt=AbstractPlus)\].

Further reading on 3A. Estrogen receptors {#bph13880-sec-0066}
-----------------------------------------
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[3C. 3‐Ketosteroid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=98) {#bph13880-sec-0067}
=======================================================================================================

Nomenclature[Androgen receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628)[Glucocorticoid receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625)Systematic nomenclatureNR3C4NR3C1HGNC, UniProt[AR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=644), [P10275](http://www.uniprot.org/uniprot/P10275)[NR3C1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7978), [P04150](http://www.uniprot.org/uniprot/P04150)Rank order of potency[dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/2911578?dopt=AbstractPlus)\]\>[testosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858)[cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869)≫[aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872), [deoxycortisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450) \[[125](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\]Selective agonists[testosterone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7100) \[[95](http://www.ncbi.nlm.nih.gov/pubmed/17574413?dopt=AbstractPlus)\], [mibolerone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2859) \[[49](http://www.ncbi.nlm.nih.gov/pubmed/10852459?dopt=AbstractPlus)\], [fluoxymesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2861) \[[61](http://www.ncbi.nlm.nih.gov/pubmed/17439112?dopt=AbstractPlus)\], [methyltrienolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2857) \[[148](http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus)\], [dromostanolone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6947)[fluticasone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7080) \[[10](http://www.ncbi.nlm.nih.gov/pubmed/10633034?dopt=AbstractPlus)\], [beclometasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7059) \[[3](#bph13880-bib-0003){ref-type="ref"}\], [methylprednisolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7088) \[[3](#bph13880-bib-0003){ref-type="ref"}\], [fluocinonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7078) \[[3](#bph13880-bib-0003){ref-type="ref"}\], [betamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7061) \[[3](#bph13880-bib-0003){ref-type="ref"}\], [budesonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7434) \[[102](http://www.ncbi.nlm.nih.gov/pubmed/21880489?dopt=AbstractPlus)\]Selective antagonists[bicalutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863) (p*K* ~i~ 7.7) \[[70](http://www.ncbi.nlm.nih.gov/pubmed/16420057?dopt=AbstractPlus)\], [PF0998425](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6698) (pIC~50~ 7.1--7.5) \[[85](http://www.ncbi.nlm.nih.gov/pubmed/18921992?dopt=AbstractPlus)\], [enzalutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6812) (pIC~50~ 7.4) \[[143](http://www.ncbi.nlm.nih.gov/pubmed/19359544?dopt=AbstractPlus)\], [nilutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864) (pIC~50~ 7.1--7.1) \[[133](http://www.ncbi.nlm.nih.gov/pubmed/9111629?dopt=AbstractPlus)\], [hydroxyflutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2862) (pEC~50~ 6.6) \[[148](http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus)\], [galeterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638) (pIC~50~ 6.4) \[[56](http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus)\], [flutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943) (p*K* ~i~ 5.4) \[[147](http://www.ncbi.nlm.nih.gov/pubmed/18571420?dopt=AbstractPlus)\][onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (pIC~50~ 7.6) \[[165](http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus)\], [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)Labelled ligands[\[^3^H\]dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3455) (Selective Agonist), [\[^3^H\]methyltrienolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3457) (Selective Agonist), [\[^3^H\]mibolerone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3456) (Agonist)[\[^3^H\]dexamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447) (Agonist)

Nomenclature[Mineralocorticoid receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626)[Progesterone receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627)Systematic nomenclatureNR3C2NR3C3HGNC, UniProt[NR3C2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7979), [P08235](http://www.uniprot.org/uniprot/P08235)[PGR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8910), [P06401](http://www.uniprot.org/uniprot/P06401)Rank order of potency[corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869), [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872) \[[58](http://www.ncbi.nlm.nih.gov/pubmed/10611474?dopt=AbstractPlus), [125](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\], [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) \[[125](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\][progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) \[[38](http://www.ncbi.nlm.nih.gov/pubmed/9667968?dopt=AbstractPlus)\]Selective agonists--[medroxyprogesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879) (Affinity at human PR‐A) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/9464360?dopt=AbstractPlus)\], [ORG2058](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3453), [levonorgestrel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2881) \[[9](http://www.ncbi.nlm.nih.gov/pubmed/6645495?dopt=AbstractPlus), [128](http://www.ncbi.nlm.nih.gov/pubmed/14670641?dopt=AbstractPlus)\]Selective antagonists[finerenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8678) (pIC~50~ 7.7) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/22791416?dopt=AbstractPlus)\], [eplerenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2876) (p*K* ~i~ 6.9) \[[5](http://www.ncbi.nlm.nih.gov/pubmed/18038968?dopt=AbstractPlus)\], [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (pIC~50~ 6.3) \[[165](http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus)\], [RU28318](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3451), [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)[ulipristal acetate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7460) (pIC~50~ 9.7) \[[123](http://www.ncbi.nlm.nih.gov/pubmed/18243712?dopt=AbstractPlus)\], [mifepristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805) (Mixed) (p*K* ~i~ 9) \[[167](http://www.ncbi.nlm.nih.gov/pubmed/12781197?dopt=AbstractPlus)\], [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (p*K* ~i~ 7.7) \[[54](http://www.ncbi.nlm.nih.gov/pubmed/8627601?dopt=AbstractPlus)\], [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)Labelled ligands[\[^3^H\]aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3452) (Selective Agonist) \[[44](http://www.ncbi.nlm.nih.gov/pubmed/16188378?dopt=AbstractPlus), [137](http://www.ncbi.nlm.nih.gov/pubmed/6320679?dopt=AbstractPlus)\] -- Rat[\[^3^H\]ORG2058](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3454) (Selective Agonist)

Comments {#bph13880-sec-0068}
--------

[\[^3^H\]dexamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447) also binds to MR in vitro. PR antagonists have been suggested to subdivide into Type I (e.g. [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882)) and Type II (e.g. [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)) groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription‐neutral complex \[[43](http://www.ncbi.nlm.nih.gov/pubmed/9528977?dopt=AbstractPlus), [82](http://www.ncbi.nlm.nih.gov/pubmed/9849965?dopt=AbstractPlus)\]. Mutations in AR underlie testicular feminization and androgen insensitivity syndromes, spinal and bulbar muscular atrophy (Kennedy\'s disease).
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----------------------------------------------
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